American Heart Journal
Volume 156, Issue 3 , Pages 527.e1-527.e9 , September 2008

Dronedarone for the control of ventricular rate in permanent atrial fibrillation: The Efficacy and safety of dRonedArone for The cOntrol of ventricular rate during atrial fibrillation (ERATO) study

  • Jean-Marc Davy, MD, PhD

      Affiliations

    • Cardiology Department, University Hospital, CHU Montpellier, Montpellier, France
    • Corresponding Author InformationReprint requests: Jean-Marc Davy, MD, PhD, Département de Cardiologie, Centre Hospitalier Universitaire de Montpellier, 371 Avenue Doyen Gaston Giraud, 34295 Montpellier, France.
    • ,
  • Martin Herold, MD

      Affiliations

    • University Hospital Kral Vinohrady, Prague, Czech Republic
    • ,
  • Christer Hoglund, MD

      Affiliations

    • Stockholm Heart Centre, Stockholm, Sweden
    • ,
  • Alphons Timmermans, MD

      Affiliations

    • Medisch Spectrum Twente, Enschede, Netherlands
    • ,
  • Antonio Alings, MD, PhD

      Affiliations

    • Amphia Hospital, Molengracht, Breda, Netherlands; and the Working Group on Cardiovascular Research, Netherlands (WCN)
    • ,
  • David Radzik, MD

      Affiliations

    • Sanofi-Aventis, Paris, France
    • ,
  • Louis Van Kempen, MD, PhD

      Affiliations

    • Hospital, Velp, Netherlands
    • ,
  • for the ERATO Study Investigators

      Affiliations

    • for a full list of the ERATO Study Investigators, see Appendix A.

Received 13 June 2007 ,Accepted 9 June 2008.

  • Image Result

    Design of the ERATO study.

    Design of the ERATO study.

  • Image Result

    Patient disposition.

    Patient disposition.

  • Image Result

    Effect of dronedarone on resting HR: mean (±SEM) ventricular rate at D0 and D14 and mean change from D0 to D14 (95% CI).

    Effect of dronedarone on resting HR: mean (±SEM) ventricular rate at D0 and D14 and mean change from D0 to D14 (95% CI).

  • Image Result

    Effect of dronedarone on mean 24-hour HR when added to standard rate-lowering therapies: mean change from D0 to D14 (95% CI).

    Effect of dronedarone on mean 24-hour HR when added to standard rate-lowering therapies: mean change from D0 to D14 (95% CI).

  • Image Result

    Effect of dronedarone on HR during maximal exercise: mean (±SEM) ventricular rate at D0 and D14 and mean change from D0 (95% CI).

    Effect of dronedarone on HR during maximal exercise: mean (±SEM) ventricular rate at D0 and D14 and mean change from D0 (95% CI).

  • Image Result

    Long-term efficacy of dronedarone in reducing mean 24-hour ventricular rate (M4 = 4 months).

    Long-term efficacy of dronedarone in reducing mean 24-hour ventricular rate (M4 = 4 months).

 The ERATO study was sponsored by Sanofi-Aventis, Paris, France.

PII: S0002-8703(08)00477-8

doi: 10.1016/j.ahj.2008.06.010

American Heart Journal
Volume 156, Issue 3 , Pages 527.e1-527.e9 , September 2008

Article Tools

* Image Usage & Resolution